Proportion of Retinopathy of Prematurity That Was Treated across Regions in the United States.


Journal

American journal of perinatology
ISSN: 1098-8785
Titre abrégé: Am J Perinatol
Pays: United States
ID NLM: 8405212

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 19 11 2019
medline: 27 11 2021
entrez: 19 11 2019
Statut: ppublish

Résumé

Retinopathy of prematurity (ROP) is the leading preventable cause of blindness in children worldwide. Major eye and visual problems are strongly linked to ROP requiring treatment. Objectives of the study are to: (1) evaluate the trends and regional differences in the proportion of treated ROP, (2) describe risk factors, and (3) examine if treated ROP predicts mortality. Retrospective data analysis was conducted using the Kids' Inpatient Database from 1997 to 2012. ROP was categorized into treated ROP (requiring laser photocoagulation or surgical intervention) and nontreated ROP. Bivariate and multivariate logistic regression analyses were performed. Out of 21,955,949 infants ≤ 12 months old, we identified 70,541 cases of ROP and 7,167 (10.2%) were treated. Over time, the proportion of treated ROP decreased ( The proportion of ROP that is surgically treated has decreased in the United States; however, there is variability among the different regions. Demographics and clinical practice may have contributed for this variability.

Identifiants

pubmed: 31739361
doi: 10.1055/s-0039-1700855
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-589

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Rowena G Cayabyab (RG)

Division of Neonatalogy, Department of Pediatrics, LAC+USC Medical Center, Keck School of Medicine, University of Southern California, Los Angeles, California.

Ashley Song (A)

Fetal and Neonatal Institute, Division of Neonatology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.

Rangasamy Ramanathan (R)

Division of Neonatalogy, Department of Pediatrics, LAC+USC Medical Center, Keck School of Medicine, University of Southern California, Los Angeles, California.

Philippe Friedlich (P)

Fetal and Neonatal Institute, Division of Neonatology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.

Ashwini Lakshmanan (A)

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Leonard D. Schaeffer Center for Health Policy and Economics, School of Pharmacy, Keck School of Medicine, University of Southern California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH